Previous Close | 2.1200 |
Open | 2.1700 |
Bid | 0.0000 x 0 |
Ask | 0.0000 x 0 |
Day's Range | 2.1000 - 2.3292 |
52 Week Range | 2.0900 - 42.4000 |
Volume | |
Avg. Volume | 88,740 |
Market Cap | 4.222M |
Beta (5Y Monthly) | -0.63 |
PE Ratio (TTM) | N/A |
EPS (TTM) | N/A |
Earnings Date | N/A |
Forward Dividend & Yield | N/A (N/A) |
Ex-Dividend Date | N/A |
1y Target Est | N/A |
Genprex (GNPX) gains 9.5% after expanding clinical study sites in the United States for the early to mid-stage study of lead candidate, Reqorsa, to treat lung cancer patients.
GENPREX (GNPX) has been upgraded to a Zacks Rank #2 (Buy), reflecting growing optimism about the company's earnings prospects. This might drive the stock higher in the near term.
BofA analysts slashed retail chain Dick's Sporting Goods (NYSE:DKS) to Neutral from Buy on Thursday with a price target of $125, down from the prior $180.